Compararative susceptibilities of escherichia coli to ceftriaxone alone and in combination with clavulanic acid

Journal of Medical Sciences

Volumn 17, Issue 1, 2009, Pages 12-15

  Jalil, Abdul ^a   Tariq, Shafiq Ahmad ^b   Niazi, Iftikhar Ud Din ^b  

^a Khyber Girls Medical College   (Pakistan)

^b KHYBER TEACHING HOSPITAL   (Pakistan)

Author keywords

Ceftriaxone; Clavulanic acid; Esherichia coli; Susceptibility

Indexed keywords

BETA LACTAMASE; CEFTRIAXONE; CLAVULANIC ACID;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISK DIFFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; ESCHERICHIA COLI; LABORATORY; NONHUMAN;

EID: 77953429271     PISSN: 19973438     EISSN: 19973446     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wiliams JD. β-lactamase inhibition and in-vitro activity of sulbactam and sulbactam/cefoperazone. Clin infect Dis 1997; 24(3): 494-497
2. Therrien C, Levesque RC. Molecular basis of antibiotic resistance and β-lactamase inhibition by mechanism - based inactivators: perspectives and future directions. FEMS Microbiol Rev 2000; 24:251-262 (Pubitemid 30332359)
3. Matagne A, Lamotte - Brasseur J, Frere JM. Catalytic properties of class A β-lactamases: efficiency and diversity. Biochem J 1998; 330: 581-598
4. MacGowan A. Break points for extendedspectrum β-lactamase producing enterobacteriaceae: pharmacokinetic/pharmacodynamic considerations. Clin Microbiol Infect 2008; 14 (Supp 1): 166-168
5. Muratani T, Yokota E, Nakane T Inoue E and Mitsuhashi S. In-vitro evaluation of the four β-lactamase inhibitors: BRL 42715, clavulanic acid, sulbactam and tazobactam. J Antimicrob Chemother 1993; 32:421-429 (Pubitemid 23295288)
6. Livermore DM. β-lactamase mediated resistance and opportunities for its control. J Anti microb Chemother 1998; 41 (suppl D): 25-41.
7. Akora M. Sulbactam containing β-lactamase inhibitor combinations. Eur Soc Clin Microbial infect Dis 2008; 14 (supply 1): 185-188
8. Handal T, Olsen I. Antimicrobial resistance with focus on oral β-lactamases Eur J oral Sci 2000; 180: 163-174
9. Walker C. Anti microbial agents and chemotherapy. In. Slots J, Taubman MA, eds. Contemporary oral microbiology and immunology. St. Louis: moby - year Book, 1992 : 242-253
10. Green wood D, Slack RCB, Pentherer JF. Escherichia, Chapter 72 In. Medical Microbiology 15th ed; 1997 : 267-275
11. Challaghan CH, Moris A, Kirby SM, Shingler AH. Novel method for detection of β-lactamase by using a chromogenic cephalosporin substrate. Antimicrob agents Chemother 1972; 1(4): 283-288
12. Finegold SM, Baron EJ. Methods for testing antimicrobial effectiveness. Chapter 13. In. Bailey and Scott's diagnostic microbiology, 7th ed; 1986. 197-205.
13. Goldstein EJC, Citron DM, Cherubin CE. Comparison of the inoculum effects of members of family enterobacteriaceae on cefoxitin and other cephalosporins, β-lactamase inhibitor combinations and the penicillin derived components of these combinations. Antimicrob agents Chemother 1991; 35(3): 560-567
14. Statford BC. In-vitro activity of new cephalosporin (HR 756) and cefazolin. Lancent ii 1976; 528-529 (Pubitemid 9014520)
15. Cormican M. Kirby Baur and Susceptibility testing in the USA: meeting report on susceptibility testing. Acad Med Lab Sci; 1999, 4-10.
16. Norby SR. Future trends in antibiotic therapy. Scand J infect Dis 1992; 83 (suppl): 41-45.
17. Drieux L, Brossier F, Sougakoff W and Jerlier V. Phenotypic detection of extended - spectrum β-lactamase production in enterobacteriaceae: review and bench guide. Eur Soc Clin Microbiol infect Dis 2008; 14 (supply.1): 90-103.
18. Ferrara A, Dos-Santos C, Cimbro M. Effect of different β-lactams in combination with β-lactamase inhibitors in the presence or absence of tobramycin against some enterobacteriaceae producing extended spectrum β-lactamases. Antimicrob agents Chemother 1998; 44(5) : 313-317 (Pubitemid 28386664)
19. Jacoby GA, Medeiros AA. More extended spectrum β-lactamases. Antimicrob agents Chemother 1991; 35 : 1697-1704.
20. Imtiaz U, Billings EM, Knox JR and Mobashery S. A Structure based analysis of the inhibition of class A β-lactamase by sulbactam. Biochem 1994; 33: 5728-5738 (Pubitemid 24184574)
21. Imtiaz U, Manavathu EK, Mobashery S and Lerner SA. Reversel of clavulanate resistance conferred by ser - 244 mutation of TEM - I β-lactamase as a result of a second mutation (Arg to ser at position 164) that enhances activity against ceftazidime. Antimicrob agents Chemother 1994; 38: 1134-1139 (Pubitemid 24150851)
22. Livermore DM, Hope R, Mushtaq S and Warner M. Orthodox and unorthodox clavaulanate combinations against extended - spectum β-lactamase producers. Eur soc Clin Microbiol infect Dis 2008; 14 (suppl I): 189-193
23. Barry Al, Jones RN and the collaborative anti microbiol susceptibility group. Criteria for disk susceptibility tests and quality control guidelines for cefoperazone - sulbactam combination. J Clin Microbiol 1998; 26(1) : 13-17.
24. Karch, Tawfik AF, Al shammary F. Antimicrobial resistance and prevalence of extended spectrum β-lactamase among clinical isolates of gram negative bacteria in Riyadh. J Chemother 1995; 7(6): 509-514